469 related articles for article (PubMed ID: 2644532)
21. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J
Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855
[TBL] [Abstract][Full Text] [Related]
22. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
24. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen.
Freedman GM; Anderson P; Li T; Ross E; Swaby R; Goldstein L
Cancer; 2006 Dec; 107(11):2552-8. PubMed ID: 17061250
[TBL] [Abstract][Full Text] [Related]
25. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
Fisher B; Jeong JH; Anderson S; Wolmark N
J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
[TBL] [Abstract][Full Text] [Related]
26. [Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients].
Petráková K; Nenutil R; Grell P; Fabian P; Zichová I; Svoboda M; Palácová M; Vyzula R
Klin Onkol; 2008; 21(5):303-8. PubMed ID: 19202962
[TBL] [Abstract][Full Text] [Related]
27. [Adjuvant endocrine treatment of postmenopausal patients with breast cancer with high risk of recurrence. 5. Results from the DBCG (Danish Breast Cancer Cooperative Group) 77C randomized trial].
Rose C; Andersen JA; Andersen KW; Axelsson CK; Blichert-Toft M; Dombernowsky P; Hansen M; Krag C; Mouridsen HT; Overgaard M
Ugeskr Laeger; 1991 Aug; 153(33):2283-7. PubMed ID: 1781047
[TBL] [Abstract][Full Text] [Related]
28. Indicators of prognosis in node-negative breast cancer.
Sigurdsson H; Baldetorp B; Borg A; Dalberg M; Fernö M; Killander D; Olsson H
N Engl J Med; 1990 Apr; 322(15):1045-53. PubMed ID: 2320064
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh.
Lancet; 1987 Jul; 2(8552):171-5. PubMed ID: 2885637
[TBL] [Abstract][Full Text] [Related]
30. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer.
Fowble B; Fein DA; Hanlon AL; Eisenberg BL; Hoffman JP; Sigurdson ER; Daly MB; Goldstein LJ
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):669-77. PubMed ID: 8690632
[TBL] [Abstract][Full Text] [Related]
31. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.
Hughes KS; Schnaper LA; Berry D; Cirrincione C; McCormick B; Shank B; Wheeler J; Champion LA; Smith TJ; Smith BL; Shapiro C; Muss HB; Winer E; Hudis C; Wood W; Sugarbaker D; Henderson IC; Norton L; ; ;
N Engl J Med; 2004 Sep; 351(10):971-7. PubMed ID: 15342805
[TBL] [Abstract][Full Text] [Related]
32. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; Deschênes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.
Fisher B; Redmond C; Brown A; Fisher ER; Wolmark N; Bowman D; Plotkin D; Wolter J; Bornstein R; Legault-Poisson S
J Clin Oncol; 1986 Apr; 4(4):459-71. PubMed ID: 2856857
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo.
Cummings FJ; Gray R; Davis TE; Tormey DC; Harris JE; Falkson G; Arseneau J
Ann Intern Med; 1985 Sep; 103(3):324-9. PubMed ID: 3896085
[TBL] [Abstract][Full Text] [Related]
35. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.
Fisher B; Redmond C; Brown A; Wickerham DL; Wolmark N; Allegra J; Escher G; Lippman M; Savlov E; Wittliff J
J Clin Oncol; 1983 Apr; 1(4):227-41. PubMed ID: 6366135
[TBL] [Abstract][Full Text] [Related]
36. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation.
Lancet; 1983 Feb; 1(8319):257-61. PubMed ID: 6130291
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial.
Delozier T; Julien JP; Juret P; Veyret C; Couëtte JE; Graic Y; Ollivier JM; de Ranieri E
Breast Cancer Res Treat; 1986; 7(2):105-9. PubMed ID: 3521767
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death.
Cummings FJ; Gray R; Tormey DC; Davis TE; Volk H; Harris J; Falkson G; Bennett JM
J Clin Oncol; 1993 Jan; 11(1):29-35. PubMed ID: 8418238
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of estrogen and progesterone receptors in non-neoplastic breast tissue of women of reproductive age exposed to tamoxifen and raloxifene: a randomized, double-blind study.
Rosal MA; da Silva BB
Breast Cancer Res Treat; 2011 Feb; 125(3):797-801. PubMed ID: 21184272
[TBL] [Abstract][Full Text] [Related]
40. Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials.
Fisher B; Redmond C; Wickerham DL; Wolmark N; Bowman D; Couture J; Dimitrov NV; Margolese R; Legault-Poisson S; Robidoux A
Ann Intern Med; 1989 Nov; 111(9):703-12. PubMed ID: 2679288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
